Elapegademase
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Elapegademase: From ADA-SCID to Diabetic Retinopathy
One-Sentence Summary
Elapegademase (Revcovi) is a PEGylated adenosine deaminase enzyme replacement therapy. The Evidence Pack lists no approved-indication text, but public labeling identifies it for adenosine deaminase severe combined immunodeficiency (ADA-SCID). The TxGNN model predicts it may be effective for diabetic retinopathy, but this is a model output only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | ADA-SCID (from public labeling; the Evidence Pack’s indication text is empty) |
| Predicted New Indication | Diabetic retinopathy |
| TxGNN Prediction Score | 99.45% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 1 (BLA761092) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the Evidence Pack. Based on known information, elapegademase is a systemic PEGylated enzyme that converts adenosine to inosine.
A link to diabetic retinopathy is conceivable but speculative. Adenosine signaling through A2A/A2B receptors is implicated in retinal angiogenesis and VEGF regulation. However, the direction of effect is unclear, because lowering adenosine could be either pro- or anti-angiogenic. A large PEGylated protein is also unlikely to reach the retina in meaningful amounts.
The other nine predictions are also eye conditions: severe nonproliferative diabetic retinopathy, diabetic cataract, and several cataract subtypes. They have near-identical scores (0.9937–0.9945), and several share exactly the same score. This points to knowledge-graph clustering around diabetic eye disease rather than independent signals. Severe nonproliferative diabetic retinopathy is a substage of the top prediction. The cataract predictions have no plausible mechanism.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| BLA761092 | Revcovi (Chiesi USA, Inc.) | Injection | Not listed in the Evidence Pack |
Safety Considerations
Please refer to the package insert for safety information. No drug interaction records were found for this drug.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score, with no trials or publications. The mechanism is speculative, and ocular delivery of a large systemic enzyme is unaddressed.
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism-of-action data, for example from DrugBank
- Preclinical evidence that adenosine deaminase replacement affects retinal angiogenesis or VEGF signaling
- An assessment of whether a systemic PEGylated enzyme can reach the retina, or whether an ocular route would be needed
- A literature and trial search for evidence linking adenosine metabolism to diabetic retinopathy
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.